Objective: To examine the relationship between the apolipoprotein E (APOE) ⑀4 genotype, medial temporal lobe atrophy, and white matter hyperintensities on magnetic resonance imaging in late-life dementias.
T HE PRESENCE of the apolipoprotein E (APOE) ⑀4 allele has been identified as a major risk factor for both sporadic and familial lateonset Alzheimer disease (AD). Located on chromosome 19 at q13.2, the APOE gene codes for 3 major isoforms: ⑀2, ⑀3, and ⑀4. An increased frequency of the APOE ⑀4 allele has been observed in subjects with AD 1 and those with other types of dementia, including dementia with Lewy bodies (DLB) [2] [3] [4] [5] and vascular dementia (VaD). [6] [7] [8] The pathological pathway through which the apolipoprotein E exerts influence has yet to be determined. In particular, it is not known whether the effects of the apolipoprotein E are specific to AD or expressed through a common pathway, independent of the diagnosis.
Recently, several studies have reported a link between the presence of APOE ⑀4 and specific morphologic changes identified on neuroimaging. Lehtovirta and colleagues, 9, 10 Tanaka et al, 11 and Juottonen et al 12 studied subjects with AD and found increased atrophy in medial temporal lobe structures on magnetic resonance imaging (MRI) in those possessing an APOE ⑀4 allele. The relationship between medial temporal lobe atrophy (MTA) on MRI and the APOE ⑀4 status in subjects with DLB and VaD has not yet been examined.
Imaging studies have also reported a high prevalence of white matter changes ORIGINAL CONTRIBUTION in subjects with AD 13, 14 and VaD. 15, 16 These lesions have been linked to vascular causes and diseases, and in postmortem studies, APOE ⑀4 has been strongly associated with cerebral amyloid angiopathy, 17, 18 suggesting the possibility of an association between APOE ⑀4 status, microvascular ischemia, and white matter lesions.
The primary aim of this study was to examine the relationship between the APOE ⑀4 status, MTA, and white matter lesions on MRI and to investigate whether any association was specific to AD or present in other dementias when associated with APOE ⑀4. Our hypotheses were that APOE ⑀4 would be associated with increased preva-lences of MTA and white matter lesions and that this association, if observed, would be independent of the diagnosis. To test these hypotheses, the APOE genotype was determined in a representative sample of subjects with AD, VaD, or DLB, and MTA and white matter lesions were rated on MRI in a manner blinded to the diagnosis and APOE status.
RESULTS
The subject characteristics and frequencies of APOE alleles are shown in Table 1 . The dementia groups were 
SUBJECTS AND METHODS

RECRUITMENT AND DIAGNOSIS OF SUBJECTS
Seventy-one subjects older than 60 years who fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 19 criteria for dementia were recruited from a community-dwelling population of patients with an informant in regular contact. Subjects were prospectively chosen from a clinical case register of consecutive referrals to Old Age Psychiatry Services, Newcastle General Hospital, Newcastle upon Tyne, England. The recruitment of subjects with DLB was supplemented by referrals to a specialist dementia clinic. The research was approved by the local ethics committee, and all subjects, as well as the nearest relative for patients, gave informed consent after the nature of the procedures had been fully explained.
Standardized clinical diagnostic criteria were used to characterize the type of dementia. The diagnoses of AD, VaD, and DLB were made in accordance with criteria of the National Institute of Neurological and Communication Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association, 20 the National Institute of Neurological Disorders and Stroke and the Association International pour la Recherche et l'Enseignement en Neurosciences, 21 and the Consortium on DLB International Workshop, 22 respectively, by consensus among 3 experienced raters (J.O'B., C.B., and I.McK.). The diagnosis was made in a manner blinded to MRI findings and APOE status. Applying these criteria, 25 subjects had AD, 24 had VaD, and 22 had DLB. Cognitive function was measured using the Mini-Mental State Examination 23 within 3 months of obtaining an MRI scan.
MRI SCANNING PROCEDURE
All scans were performed on a 1.0-T MRI scanner (Siemens Magnetom Impact; Siemens Analytical X-ray Instruments, Erlangen, Germany). To assess MTA, T 1 -weighted coronal images of the whole temporal lobe were obtained with a slice thickness of 5 mm and no interslice gap. These images were acquired by reformatting a 3-dimensional data set perpendicular to the long axis of the hippocampus (magnetization prepared rapid-acquisition gradient echo: repetition time, 11.4 milliseconds; echo time, 4.4 milliseconds; inversion time, 400 milliseconds; time delay, 50 milliseconds; matrix, 256 ϫ 256; and slice thickness, 1 mm).
To assess white matter lesions, whole-brain axial images of 5-mm thickness (0.5-mm gap) were acquired using proton density-weighted and T 2 -weighted turbo or fastspin echo sequences (rapid acquisition with relaxation enhancement: repetition time, 2800 milliseconds; echo time, 14/85 milliseconds; matrix, 256 ϫ 256; field of view, 230 mm, giving a pixel size of 0.92 ϫ 0.92 mm; and acquisition time, 4 minutes 13 seconds).
MTA AND WHITE MATTER RATING
All scans were rated with the diagnosis and the APOE genotype blinded. A standardized scale 24 was used to rate left and right MTA from copies of T 1 -weighted coronal images. This scale rates MTA as 0 (indicating absent) to 4 (indicating severe) according to the width of the surrounding cerebrospinal fluid spaces (choroidal fissure and temporal horns) and the height of the hippocampal formation, which includes the hippocampus proper, the subiculum, and the parahippocampal and dentate gyri. The scans were scored using the following criteria: 0 = no change; 1 = mild increase in the width of the choroid fissure, normal temporal horn width, and the height of hippocampal matched for age, sex, age at onset of illness, duration of illness, and cognitive function. No significant differences were found in the frequency of APOE ⑀2, ⑀3, and ⑀4 among the dementia groups, although subjects with AD had the highest frequency of APOE ⑀4.
When the subjects with dementia were divided according to the presence (n = 38) or absence (n = 33) of the APOE ⑀4 allele, no significant differences were noted among the groups in age (⑀4 present vs ⑀4 absent: 77.8 vs 76.7 years), age at onset of illness (74.7 vs 73.0 years), duration of illness (36.1 vs 44.2 months), education (9.6 vs 9.6 years), or Mini-Mental State Examination scores (mean ± SD, 15.4 ± 6.1 vs 16.7 ± 5.5). Subjects possessing an APOE ⑀4 allele, however, were more likely to be female (23 vs 11, 2 1 = 5.2; P = .02) and to have a family history of dementia (14 vs 4 subjects; Fisher exact test, P = .03).
The Figure summarizes the results of the ratings of MTA, periventricular hyperintensities, and white matter hyperintensities for all subjects with dementia according to the absence of an APOE ⑀4 allele (⑀n = 33) and the presence of 1 (⑀n = 31) or 2 APOE ⑀4 alleles (⑀n = 7). No significant associations were noted between APOE ⑀4 status and MTA (mean score: 0 ⑀4 = 4.5, 1 ⑀4 = 4.5, and 2 ⑀4 = 4.3; P = .90), periventricular hyperintensities (0 ⑀4 = 3.3, 1 ⑀4 = 3.1, and 2 ⑀4 = 2.9; P = .83), and white matter hyperintensities (0 ⑀4 = 5.3, 1 ⑀4 = 4.9, and 2 ⑀4 = 4.9; P = .79).
When each dementia group was analyzed separately according to the presence or absence of the APOE ⑀4 allele, no significant differences were noted between MRI ratings and the presence of ⑀4 in subjects with AD, VaD, or DLB, as shown in Table 2 . formation; 2 = moderate increase in the width of the choroid fissure, mild increase in the width of the temporal horn, and mild decrease in the height of the hippocampal formation; 3 = severe increase in the width of the choroid fissure, moderate increase in the width of the temporal horn, and moderate decrease in the height of the hippocampal formation; and 4 = severe increase in the width of the choroid fissure and temporal horn and severe decrease in the height of the hippocampal formation. Scans were rated by consensus among 3 experienced raters (J.O'B., A.G., and P.S.). For the purposes of analysis, left and right MTA scores were summed to give a combined score, ranging from 0 to 8. White matter lesions were rated using a semiquantitative scale 25 from copies of proton density-and T 2weighted axial images by an experienced rater (P.S.). The scale provided a measurement of periventricular hyperintensities and deep white matter hyperintensities. Periventricular hyperintensities (maximum score = 6) represented the combined score for bands and frontal and occipital caps according to their size (0 = absent; 1 = Յ5 mm in width; and 2 = Ͼ5 mm and Ͻ10 mm in width). White matter hyperintensities were rated in 4 regions: frontal, temporal, parietal, and occipital (0-6 in each area, maximum total score = 24) according to the size and number of lesions (0 = absent; 1 = Ͻ3 mm, Յ5 lesions; 2 = Ͻ3 mm, Ն6 lesions; 3 = 4-10 mm, Յ5 lesions; 4 = 4-10 mm, Ն6 lesions; 5 = Ն11 mm, Ն1 lesions; and 6 = confluent).
DETERMINATION OF APOE GENOTYPE
The APOE genotypes were analyzed using the standard polymerase chain reaction method. Genomic DNA was isolated from whole blood using a proprietary extraction method according to the manufacturer's instructions (QIAamp Blood Kit; QIAGEN, Crawley, England).
Amplification of the APOE gene containing the allelic sites was performed by a modification of the method of Wenham et al 26 and Hixson and Vernier. 27 The following polymerase chain reaction primers were used in the amplification: forward: 5Ј-TCCAAGGAGCTGCAGGCGGCGCA-3Ј, and reverse: 5Ј-ACAGAATTCGCCCCGGCCTGGTACACTGCCA-3Ј.The reactions were performed in a final 50-mL volume of standard buffer containing 15 pmol of each primer; Taq polymerase (Pharmacia Biotech Ltd, St Albans, England), 1.0 U; 10% dimethyl sulfoxide; 200 mmol/L of each deoxynucleotide; and DNA, 200 ng. Reaction conditions were an initial denaturation at 95°C for 5 minutes, followed by 40 cycles of annealing at 65°C for 30 seconds, an extension at 70°C for 90 seconds, and denaturation at 94°C for 30 seconds. The resultant amplification products were then digested overnight at 37°C with CfoI enzyme (Boehringer, Lewes, England), 2.5 U, in the buffer supplied. Following digestion, the polymerase chain reaction products were electrophoresed through a composite 3% Nu Sieve and 1% standard agarose (Flowgen, Lichfield, England) gel, and the bands were visualized using ethidium bromide fluorescence.
STATISTICAL ANALYSIS
A commercial statistical software package (Statistical Package for the Social Sciences for Windows, release 7.5; SPSS Institute, Inc, Chicago, Ill) was used for data analysis. Differences between groups on continuous variables were assessed using analysis of variance with the post hoc Scheffé test. For nonparametric data, the Kruskal-Wallis test, Mann-Whitney test, or Pearson 2 statistic was used as appropriate, with the Fisher exact probability test calculated for 2 ϫ 2 tables when the expected cell frequency was less than 5. All statistical tests were 2-tailed and were regarded as significant at PϽ.05.
COMMENT
No association was found between the presence of the APOE ⑀4 allele and MTA and white matter lesions on MRI in subjects with late-onset AD, VaD, or DLB. The frequency of APOE ⑀4 in the different dementia groups was consistent with that in previous studies, 1, 3, 5, 7, 8 and in common with other findings, subjects with APOE ⑀4 were more likely to have a family history of dementia in line with other reports. 1 Overall, subjects were well matched for age, age at onset of illness, duration of illness, and the severity of cognitive impairment.
MEDIAL TEMPORAL LOBE ATROPHY
Our hypothesis of an association between the presence of APOE ⑀4 and MTA was not supported by the findings of this study. Furthermore, subjects homozygous for the APOE ⑀4 allele had similar MTA ratings as those with 1 allele, and, therefore, we did not observe an ⑀4 allele dosage effect, as reported by Lehtovirta and colleagues. 9, 10 Several factors may explain the discrepancy between the findings of this study and those [9] [10] [11] [12] reporting an association between APOE ⑀4 and atrophy of medial temporal lobe structures. Lehtovirta et al 9,10 and Juottonen et al 12 used volumetric measurements to assess atrophy of the hippocampus and the entorhinal cortex, respectively. By comparison, our ratings of MTA may have lacked the sensitivity to detect small changes in volume. Alternatively, subjects in our study were older, and the association between the possession of the APOE ⑀4 allele and subsequent disease may weaken with advancing age, in parallel with the diminishing effect of APOE ⑀4 on the risk of dementia developing. Although subjects in a study by Tanaka et al 11 were of an equivalent age or even older, they were fewer (n = 34 vs 71), and the authors used a different scanning protocol (acquiring thicker slices from a lowresolution scanner) and method to rate atrophy.
The results of this study are consistent with the findings of Jack et al. 28 Examining subjects of a similar age, they found that the APOE ⑀4 genotype and hippocampal atrophy were independently linked with AD. They suggested that the lack of an association between APOE ⑀4 and hippocampal atrophy could be explained by the differential association between hippocampal atrophy and the neurofibrillary tangle burden on the one hand and a putative link between APOE ⑀4 and plaque burden on the other.
WHITE MATTER LESIONS
Our hypothesis of an association between the possession of APOE ⑀4 and white matter lesions was, again, not supported by our findings. Skoog et al, 29 likewise, found no direct link between APOE ⑀4 and white matter lesions on computed tomography of subjects aged 85 years with AD or VaD. Other studies have also failed to find an association between APOE ⑀4 and white matter lesions on MRI in normal elderly subjects 30 and those with Dutch hereditary cerebral angiopathy. 31 Overall, this finding indicates that the APOE ⑀4 allele is unlikely to play a direct role in the pathogenesis of white matter lesions in late-onset dementias, although given the variety of disorders underlying the development of white matter lesions, 32 confirmatory clinicopathological studies are necessary. Interestingly, the data are consistent with reports postulating that the APOE ⑀4 allele and cerebrovascular disease, including white matter lesions, are independent but synergistic risk factors for the development of dementia. 29, 33 
CLINICAL VS PATHOLOGICAL STUDIES
A possible criticism of this and other antemortem studies would be the reliance on standardized clinical, rather than pathological, diagnoses. This might account for some of the homogeneity among the diagnostic groups, given that a proportion of patients with clinical diagnoses of late-onset dementias turn out to have overlapping features on pathological examination.
The role of APOE in the pathogenesis of dementias remains to be determined, and so far, postmortem studies have produced conflicting results. Although several studies have failed to find a specific association between APOE ⑀4 status and the type or amount of disease, [34] [35] [36] [37] others have reported isoform-specific associations with impaired neural plasticity, 38 neurofibrillary tangle formation, 39 amyloid deposition, 40, 41 and cholinergic dysfunction. 42 In contrast, a consistent pattern is emerging from antemortem studies indicating that a range of clinical changes, including the severity and pattern of cognitive impairment, noncognitive symptoms, and neurologic features, are not influenced by APOE ⑀4 genotype. [43] [44] [45] [46] [47] [48] Although controversial, taken together, these clinical studies suggest that APOE ⑀4 can modify the risk of acquiring dementia but not subsequent pathological processes. *Values are given as mean scores. MRI indicates magnetic resonance imaging; DLB, dementia with Lewy bodies; AD, Alzheimer disease; and VaD, vascular dementia. Differences between APOE ⑀4 status and imaging variables for dementia groups were not significant.
